# Citizens Financial Services Inc: financial statements, quarterly

CZFS · Nasdaq · CIK 739421 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/czfs.md) · [Financials](/companies/czfs/financials.md) · [Filings](/companies/czfs/filings.md) · [Insiders](/companies/czfs/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/czfs/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [2.6](/filings/0001140361-24-045479.md) | [2.3 d](/filings/0001140361-26-009103.md) | [2.4](/filings/0001140361-25-017798.md) | [2.4](/filings/0001140361-25-029315.md) | [2.5](/filings/0001140361-25-040779.md) | [2.3 d](/filings/0001140361-26-009103.md) | [2.4](/filings/0001140361-26-019398.md) | [2.4](/filings/0001140361-26-031479.md) | [2.8](/filings/0001140361-25-040779.md) | [2.3 d](/filings/0001140361-26-009103.md) | [2.3](/filings/0001140361-26-019398.md) | [2.4](/filings/0001140361-26-031479.md) |
| Interest expense | $m | [14.3](/filings/0001140361-23-051966.md) | [16.7 d](/filings/0001140361-24-011948.md) | [17.0](/filings/0001140361-24-025172.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.6](/filings/0001140361-24-045479.md) | [1.7 d](/filings/0001140361-26-009103.md) | [1.5](/filings/0001140361-25-017798.md) | [1.1](/filings/0001140361-25-029315.md) | [1.7](/filings/0001140361-25-040779.md) | [1.8 d](/filings/0001140361-26-009103.md) | [1.8](/filings/0001140361-26-019398.md) | [2.0](/filings/0001140361-26-031479.md) | [2.4](/filings/0001140361-25-040779.md) | [2.6 d](/filings/0001140361-26-009103.md) | [2.3](/filings/0001140361-26-019398.md) | [2.2](/filings/0001140361-26-031479.md) |
| Net income | $m | [7.5](/filings/0001140361-24-045479.md) | [7.5 d](/filings/0001140361-26-009103.md) | [7.0](/filings/0001140361-25-017798.md) | [5.3](/filings/0001140361-25-029315.md) | [7.5](/filings/0001140361-25-040779.md) | [8.0 d](/filings/0001140361-26-009103.md) | [7.6](/filings/0001140361-26-019398.md) | [8.5](/filings/0001140361-26-031479.md) | [10.0](/filings/0001140361-25-040779.md) | [10.5 d](/filings/0001140361-26-009103.md) | [10.4](/filings/0001140361-26-019398.md) | [10.2](/filings/0001140361-26-031479.md) |
| Diluted EPS | $ per share | [1.59](/filings/0001140361-24-045479.md) | not reported | [1.48](/filings/0001140361-25-017798.md) | [1.10](/filings/0001140361-25-029315.md) | [1.57](/filings/0001140361-25-040779.md) | not reported | [1.59](/filings/0001140361-26-019398.md) | [1.76](/filings/0001140361-26-031479.md) | [2.09](/filings/0001140361-25-040779.md) | not reported | [2.16](/filings/0001140361-26-019398.md) | [2.12](/filings/0001140361-26-031479.md) |
| Basic EPS | $ per share | [1.59](/filings/0001140361-24-045479.md) | not reported | [1.48](/filings/0001140361-25-017798.md) | [1.10](/filings/0001140361-25-029315.md) | [1.57](/filings/0001140361-25-040779.md) | not reported | [1.59](/filings/0001140361-26-019398.md) | [1.76](/filings/0001140361-26-031479.md) | [2.09](/filings/0001140361-25-040779.md) | not reported | [2.16](/filings/0001140361-26-019398.md) | [2.12](/filings/0001140361-26-031479.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [43.3](/filings/0001140361-23-051966.md) | [52.8](/filings/0001140361-25-007274.md) | [29.6](/filings/0001140361-24-025172.md) | [38.4](/filings/0001140361-24-036304.md) | [36.8](/filings/0001140361-24-045479.md) | [42.2](/filings/0001140361-26-009103.md) | [36.8](/filings/0001140361-25-017798.md) | [49.5](/filings/0001140361-25-029315.md) | [31.1](/filings/0001140361-25-040779.md) | [34.3](/filings/0001140361-26-031479.md) | [33.1](/filings/0001140361-26-019398.md) | [39.4](/filings/0001140361-26-031479.md) |
| Total assets | $m | [2,959](/filings/0001140361-23-051966.md) | [2,975](/filings/0001140361-25-007274.md) | [2,921](/filings/0001140361-24-025172.md) | [2,948](/filings/0001140361-24-036304.md) | [3,026](/filings/0001140361-24-045479.md) | [3,026](/filings/0001140361-26-009103.md) | [3,016](/filings/0001140361-25-017798.md) | [2,967](/filings/0001140361-25-029315.md) | [3,056](/filings/0001140361-25-040779.md) | [3,065](/filings/0001140361-26-031479.md) | [3,026](/filings/0001140361-26-019398.md) | [3,192](/filings/0001140361-26-031479.md) |
| Total liabilities | $m | [2,697](/filings/0001140361-23-051966.md) | [2,696](/filings/0001140361-25-007274.md) | [2,638](/filings/0001140361-24-025172.md) | [2,661](/filings/0001140361-24-036304.md) | [2,728](/filings/0001140361-24-045479.md) | [2,726](/filings/0001140361-26-009103.md) | [2,708](/filings/0001140361-25-017798.md) | [2,654](/filings/0001140361-25-029315.md) | [2,729](/filings/0001140361-25-040779.md) | [2,727](/filings/0001140361-26-031479.md) | [2,683](/filings/0001140361-26-019398.md) | [2,839](/filings/0001140361-26-031479.md) |
| Shareholders' equity | $m | [263](/filings/0001140361-24-045479.md) | [280](/filings/0001140361-26-009103.md) | [283](/filings/0001140361-25-029315.md) | [286](/filings/0001140361-25-040779.md) | [299](/filings/0001140361-25-040779.md) | [300](/filings/0001140361-26-031479.md) | [308](/filings/0001140361-26-031479.md) | [314](/filings/0001140361-26-031479.md) | [328](/filings/0001140361-25-040779.md) | [338](/filings/0001140361-26-031479.md) | [344](/filings/0001140361-26-031479.md) | [353](/filings/0001140361-26-031479.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [7.4 d](/filings/0001140361-24-045479.md) | [16.2 d](/filings/0001140361-26-009103.md) | [13.5](/filings/0001140361-25-017798.md) | [3.0 d](/filings/0001140361-25-029315.md) | [6.2 d](/filings/0001140361-25-040779.md) | [10.5 d](/filings/0001140361-26-009103.md) | [10.9](/filings/0001140361-26-019398.md) | [6.0 d](/filings/0001140361-26-031479.md) | [2.9 d](/filings/0001140361-25-040779.md) | [16.7 d](/filings/0001140361-26-009103.md) | [18.0](/filings/0001140361-26-019398.md) | [(0.1) d](/filings/0001140361-26-031479.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001140361-24-045479.md) | [0.3 d](/filings/0001140361-26-009103.md) | [0.1](/filings/0001140361-25-017798.md) | [0.1 d](/filings/0001140361-25-029315.md) | [0.6 d](/filings/0001140361-25-040779.md) | [0.5 d](/filings/0001140361-26-009103.md) | [0.6](/filings/0001140361-26-019398.md) | [0.5 d](/filings/0001140361-26-031479.md) | [0.1 d](/filings/0001140361-25-040779.md) | [0.1 d](/filings/0001140361-26-009103.md) | [0.1](/filings/0001140361-26-019398.md) | [0.3 d](/filings/0001140361-26-031479.md) |
| Dividends paid | $m | [2.3 d](/filings/0001140361-24-045479.md) | [2.3 d](/filings/0001140361-26-009103.md) | [2.3](/filings/0001140361-25-017798.md) | [2.3 d](/filings/0001140361-25-029315.md) | [2.3 d](/filings/0001140361-25-040779.md) | [2.3 d](/filings/0001140361-26-009103.md) | [2.4](/filings/0001140361-26-019398.md) | [2.4 d](/filings/0001140361-26-031479.md) | [2.4 d](/filings/0001140361-25-040779.md) | [2.4 d](/filings/0001140361-26-009103.md) | [2.4](/filings/0001140361-26-019398.md) | [2.5 d](/filings/0001140361-26-031479.md) |
| Share repurchases | $m | [0.3 d](/filings/0001140361-24-045479.md) | [0.0 d](/filings/0001140361-26-009103.md) | [0.0](/filings/0001140361-25-017798.md) | [0.0 d](/filings/0001140361-25-029315.md) | [0.1 d](/filings/0001140361-25-040779.md) | [(0.0) d](/filings/0001140361-26-009103.md) | [0.1](/filings/0001140361-26-019398.md) | [0.2 d](/filings/0001140361-26-031479.md) | [0.1 d](/filings/0001140361-25-040779.md) | [(0.0) d](/filings/0001140361-26-009103.md) | [0.2](/filings/0001140361-26-019398.md) | [0.1 d](/filings/0001140361-26-031479.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [4,007](/filings/0001140361-23-051966.md) | [4,005](/filings/0001140361-24-025172.md) | [4,160](/filings/0001140361-24-036304.md) | [4,747](/filings/0001140361-24-045479.md) | [4,748](/filings/0001140361-25-017798.md) | [4,801](/filings/0001140361-25-029315.md) | [4,798](/filings/0001140361-25-040779.md) | [4,799](/filings/0001140361-26-019398.md) | [4,800](/filings/0001140361-26-031479.md) | [4,798](/filings/0001140361-25-040779.md) | [4,799](/filings/0001140361-26-019398.md) | [4,802](/filings/0001140361-26-031479.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 4,809,855 at 2026-07-29, from the cover of the [10-Q filed 2026-08-06](/filings/0001140361-26-031479.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.